Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACP1 | P24666 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.43 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17721582 | 0.90 | ACP1 (0.45) | NMT1MEN1KMT2AACP1CHRNB4 | |
| SCHEMBL16928554 | 0.88 | HRH2 (0.43) | NMT1ACP1CHRNB4CHRNA3HRH2 | |
| SCHEMBL19873488 | 0.85 | GBA1 (0.50) | NMT1MEN1KMT2AACP1CHRNB4 | |
| SCHEMBL17721487 | 0.85 | TLR9 (0.47) | NMT1MEN1KMT2AACP1CHRNB4 | |
| SCHEMBL16928011 | 0.84 | ACP1 (0.48) | NMT1ACP1HRH2HRH1HRH3 | |
| SCHEMBL19873471 | 0.84 | NMT1 (0.47) | NMT1MEN1KMT2AACP1CHRNB4 | |
| SCHEMBL16928133 | 0.83 | CHRM3 (0.39) | NMT1ACP1CHRNB4CHRNA3HRH2 | |
| SCHEMBL16928348 | 0.83 | CHRM3 (0.39) | NMT1ACP1CHRNB4CHRNA3HRH2 | |
| SCHEMBL16928309 | 0.83 | ACP1 (0.47) | NMT1ACP1CHRNB4CHRNA3HRH2 | |
| SCHEMBL16928205 | 0.83 | NMT1 (0.51) | NMT1MEN1KMT2AACP1CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970153-B1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | THE US SECRETARY OF THE ARMY ON BEHALF OF WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2018-02-21 | — | — | EP | claimed |
| US-9334246-B2 | Substituted triazines for malaria treatment and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2016-05-10 | — | — | US | claimed |
| EP-3351538-A1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | The United States of America, as represented by The Secretary of The Army, on behalf of Walter Reed Army Institute of Research (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-2970153-B1 | TRIAZINE COMPOUNDS AND COMPOSITIONS THEREOF AND METHODS FOR TREATING MALARIA AND CHEMOPROPHYLAXIS | THE US SECRETARY OF THE ARMY ON BEHALF OF WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9700562-B2 | Triazine compounds and compositions thereof and methods for treating malaria and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160213675-A1 | Triazine Compounds and Compositions Thereof and Methods for Treating Malaria and Chemoprophylaxis | WALTER REED ARMY INST OF RES THE USA AS REPRESENTED BY THE SEC OF THE ARMY ON BEHALF OF THE (US) | 2016-07-28 | — | — | US | disclosed |
| US-9334246-B2 | Substituted triazines for malaria treatment and chemoprophylaxis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY, ON BEHALF OF THE WALTER REED ARMY INSTITUTE OF RESEARCH (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150210652-A1 | Substituted Triazines for Malaria Treatment and Chemoprophylaxis | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210652-A1 | Substituted Triazines for Malaria Treatment and Chemoprophylaxis | CYP3A5, HCCS, COX15 | NMT1 912/4885MEN1 2938/4885KMT2A 490/4885 |
| US-20160213675-A1 | Triazine Compounds and Compositions Thereof and Methods for Treating Malaria and Chemoprophylaxis | HCCS, CYP3A5, COX15 | NMT1 1382/4885MEN1 2583/4885KMT2A 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.